Expertise in
5
conditions

Dr. Scott J. Lee

Internal Medicine
Kaiser Permanente
South Bay Medical Center
25825 S Vermont Ave, 
Harbor City, CA 
Accepting New Patients
Offers Telehealth
Expertise in
5
conditions
Kaiser Permanente
South Bay Medical Center
25825 S Vermont Ave, 
Harbor City, CA 

Overview

Scott Lee is a primary care provider, practicing in Internal Medicine in Harbor City, California.

Dr. Lee is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

He is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 12 clinical trials. Dr. Lee is currently accepting new patients.

Specialties

Internal Medicine

Hospital Affiliations

Kaiser Foundation Hospital - South Bay

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

South Bay Medical Center
25825 S Vermont Ave, Harbor City, CA 90710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Other
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Enrollment Status: Terminated
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drug: TAK-018
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study
Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

58 Total Publications

Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.
Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.
Journal: Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
Published: July 18, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine
Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine

Cancer Center Of Southern California

2811 Wilshire Blvd, 
Santa Monica, CA 
 (20.1 miles away)
310-552-9999
Experience:
51+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sant Chawla is an Internal Medicine provider practicing medicine in Santa Monica, California. He has been practicing medicine for over 51 years. Dr. Chawla is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is board certified in American Board Internal Medicine.

Expertise in
16
conditions
Dr. Charles Bernstein
Internal Medicine
Expertise in
16
conditions
Dr. Charles Bernstein
Internal Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (21.0 miles away)
310-794-9718
Languages Spoken:
English

Charles Bernstein is an Internal Medicine provider practicing medicine in Los Angeles, California. Dr. Bernstein is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

Expertise in
7
conditions
Dr. Eric Daar
Internal Medicine
Expertise in
7
conditions
Dr. Eric Daar
Internal Medicine

Harbor-UCLA Medical Center

1000 W Carson St, 
Torrance, CA 
 (2.9 miles away)
310-222-2365
Languages Spoken:
English
See accepted insurances

Eric Daar is an Internal Medicine provider practicing medicine in Torrance, California. Dr. Daar is highly rated in 7 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, COVID-19, AIDS Dementia Complex, and Myelitis.

Frequently Asked Questions about Dr. Scott J. Lee

How do I make an appointment with Dr. Scott J. Lee?

You can book an appointment with Dr. Scott J. Lee by calling their office at 833-574-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott J. Lee a top-rated expert for Viral Gastroenteritis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott J. Lee is classified as an Distinguished expert for Viral Gastroenteritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott J. Lee specialize in?

While Dr. Scott J. Lee is a Internal Medicine, they have specific expertise in Viral Gastroenteritis, Crohn's Disease, and Colitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Scott J. Lee participate in research or clinical trials?

Yes. Dr. Scott J. Lee has published 58 articles and abstracts on conditions like Viral Gastroenteritis. You can view a list of Dr. Scott J. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott J. Lee accept my insurance?

Dr. Scott J. Lee accepts most major insurance plans, including Anthem BCBS and Managed Medicaid. We recommend calling the office directly at 833-574-2273 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile